$PULM Getting closer to the moment Polaris and Arch envisioned years back. And spawned in DARPA Research labs 10+ years ago. Pulmatrix has been around for 10 years -- on the public markets for 5. Having a CEO's prerogative solely focused on G2M opportunities says a lot about where they are in their value-lifecycle. Running on a lean organization which licenses/partners out with leading healthcare companies, pretty sweet business model.
I guarantee you they are well aware of all opportunities.
Additionally -- attention to the pulmonary markets is way up as a result of cv-19 -- creating a fundamentally extremely bullish environment for their exact market space at least the next 5+ years. Think about it -- they are converting already in use worldwide leading oral/capsule pills into inhalers, increasing safety, lowering dosage, and being more effective.
Pulmazole is their first G2M attempt, with Cipla, a 65% respiratory market share in India. They are projecting $3.5-$5B worldwide -- they are not fucking around. The base-product (Itraconazole) is now being researched in clincal Trials in Belgium as of 3/25 for CV-19. FDA has already fast-tracked Pulmazole just 60 days ago.
J&J joined up under their lung cancer initiative. They put $100M cash on the table -- that's 4x their first deal of $22M with cipla.
It's pretty clear what is going on. Exact prices when, a fools errand and missing the point. The stakes are heating up every day. All imo.
PT1: $5
PT2: $10
PT3: $20
PTMania: $50-$100+
News 
Market Data 
Discover 
